
    
      The study is designed to examine the efficacy and safety of AD182 to treat obstructive sleep
      apnea. The study is a three-period single-dose randomized crossover design in which patients
      will undergo overnight polysomnographic (PSG) testing with dosing of one of the following 3
      treatments: AD182, AD504, or Placebo. Participants will return 1 week after their final
      crossover PSG for an end of study (EOS) Visit.
    
  